| A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) (NCT05343455) | Journey Medical Corporation | 2022-03-29 |
| A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. (NCT05296629) | Journey Medical Corporation | 2022-03-14 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea (NCT05150587) | Alfasigma S.p.A. | 2021-10-05 |
| A Safety and Efficacy Study to Evaluate Rosacea (NCT03883945) | AiViva BioPharma, Inc. | 2021-07-01 |
| Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties (NCT05675501) | Sol-Gel Technologies, Ltd. | 2020-06-10 |
| Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (NCT03667222) | BioPharmX, Inc. | 2018-09-18 |
| Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test (NCT03864978) | Alfasigma S.p.A. | 2018-06-22 |
| A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea (NCT03564119) | Sol-Gel Technologies, Ltd. | 2018-06-21 |
| A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea (NCT03448939) | Sol-Gel Technologies, Ltd. | 2018-06-18 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea (NCT03263273) | Hovione Scientia Limited | 2017-10-30 |
| A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea (NCT03276936) | Vyne Therapeutics Inc. | 2017-09-05 |
| Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea (NCT03079531) | Anne Chang | 2017-06-21 |
| Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (NCT02601963) | Vyne Therapeutics Inc. | 2015-09-01 |
| A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea (NCT02393937) | bioRASI, LLC | 2015-02-01 |
| A 21 Day Pharmacokinetics Study in Papulopustular Rosacea (NCT02028286) | Maruho Co., Ltd. | 2014-01-01 |
| An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema (NCT01933464) | University of California, San Diego | 2013-08-01 |
| A Twelve Week Safety and Efficacy Study in Rosacea (NCT01784133) | Maruho Co., Ltd. | 2013-03-01 |
| Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea (NCT01872715) | Galderma R&D | 2013-03-01 |
| Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients (NCT02052999) | Amorepacific Corporation | 2013-02-01 |
| Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea (NCT01555463) | LEO Pharma | 2012-09-01 |
| CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study (NCT01493947) | Galderma R&D | 2012-04-01 |
| Phase 3 Papulopustular Rosacea Study (NCT01494467) | Galderma R&D | 2011-12-01 |
| Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea (NCT01257919) | LEO Pharma | 2011-01-01 |
| Open Label Pilot Study of Apremilast in Treatment of Rosacea (NCT01045551) | Julian M. Mackay-Wiggan | 2010-06-01 |
| Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea (NCT01025635) | LEO Pharma | 2009-12-01 |
| Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea (NCT00855595) | LEO Pharma | 2009-02-01 |
| Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea (NCT00617903) | LEO Pharma | 2008-01-01 |
| A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily (NCT00417937) | LEO Pharma | 2007-01-01 |